ReviewCancers2020
Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Biomarkers Regulated by Lipid-Soluble Vitamins in Glioblastoma.Nutrients · 2022Pooled it
- Study of Adaptive Radiotherapy for High-Grade Glioma Based on Interfraction MRI.Cancer medicine · 2026Trial
- Raloxifene suppresses growth and promotes intrinsic apoptotic signaling in C6 glioma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- KDM5C-regulated SIX5 promotes glioblastoma progression through transcriptional activation of UBE2C and enhancement of the Warburg effect.Frontiers in immunology · 2026Article
- Cannabidiol Suppresses Glioma Growth and Limits Invasion Partly Through an LOXL2-Associated EMT-Like Program.BioMed research international · 2026Article
- Small molecular weight polyfluoroalkyl phosphonates induce ROS-mediated cytotoxicity in glioblastoma cells: a molecular mechanism study.Scientific reports · 2025Article
- Towards non-invasive diagnosis of glioblastoma: identifying metabolic biomarkers in liquid biopsies using a ROC-based approach.Discover oncology · 2025Article
- Nanostructured lipid carriers for enhanced batimastat delivery across the blood-brain barrier: an in vitro study for glioblastoma treatment.Drug delivery and translational research · 2025Article
- Hybrid classical and quantum computing for enhanced glioma tumor classification using TCGA data.Scientific reports · 2025Article
- Analysis of Overall Survival in High-Grade Glioma Patients Treated With Surgery and Adjuvant Therapy.Cureus · 2025Article
- Review
- Article
- Innovative perspectives on glioblastoma: the emerging role of long non-coding RNAs.Functional & integrative genomics · 2025Review
- Stem the blood flow: beneficial impact of bevacizumab on survival of subventricular zone glioblastoma patients.Journal of neuro-oncology · 2025Article
- Role and mechanisms of exercise therapy in enhancing drug treatment for glioma: a review.Frontiers in immunology · 2025Review
- Citronellol Induces Apoptosis via Differential Regulation of Caspase-3, NF-κB, and JAK2 Signaling Pathways in Glioblastoma Cell Line.Food science & nutrition · 2025Article
- Astaxanthin is a Novel Candidate for Glioblastoma Treatment? A Review.Current medicinal chemistry · 2025Review
- Impact ofBiomolecules & biomedicine · 2024Article
- Regulation of autophagy by non-coding RNAs in human glioblastoma.Medical oncology (Northwood, London, England) · 2024Review
- Circulating Liquid Biopsy Biomarkers in Glioblastoma: Advances and Challenges.International journal of molecular sciences · 2024Review
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma is one of the most common and detrimental forms of solid brain tumor, with over 10,000 new cases reported every year in the United States. Despite aggressive multimodal treatment approaches, the overall survival period is reported to be less than 15 months after diagnosis. A widely used approach for the treatment of glioblastoma is surgical removal of the tumor, followed by radiotherapy and chemotherapy. While there are several drugs available that are approved by the Food and Drug Administration (FDA), significant efforts have been made in recent years to develop new chemotherapeutic agents for the treatment of glioblastoma. This review describes the molecular targets and pathogenesis as well as the current progress in chemotherapeutic development and other novel therapies in the clinical setting for the treatment of glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.